Discover our latest news, updates and press releases
October 23, 2022
DAKAR, SENEGAL – October 24, 2022 Institut Pasteur de Dakar (IPD) has today announced the launch of a new program to advance the development of a measles and rubella vaccine for manufacture in Senegal. IPD, through a grant by the Bill & Melinda Gates Foundation, will deploy Batavia Biosciences’ Hip-Vax intensified production process for GMP […]
October 17, 2022
Univercells, a global life science company providing all-round solutions for biologics manufacturing, has raised € 44 million through the first close of its Series D financing round. In addition to the support of existing private and public shareholders, Univercells is very pleased to welcome prominent new investors from Belgium and the United States. Brussels (Belgium), […]
June 20, 2022
A year after the establishment of the mRNA Vaccine Technology Transfer Hub, Afrigen and Univercells enter a new agreement to develop the first African-owned COVID-19 vaccine CAPE TOWN (SOUTH AFRICA) & BRUSSELS (BELGIUM), JUNE 21, 2022 – One year since the establishment of the mRNA Vaccine Technology Transfer Hub, a collaboration between two of the […]
April 26, 2022
Jumet, Belgium, April 27, 2022 Univercells S.A., a Belgian biotech company dedicated to ensuring that everyone has access to biologics everywhere in the world, announced today that RLM Consulting SRL joined the Group as a new affiliate. RLM Consulting is a Belgian-based company that was created in 2006 and that provides regulatory affairs support at […]
March 29, 2022
Univercells, a Belgian biotech company dedicated to ensuring that everyone has access to biologics everywhere in the world, was visited today by Ministers Christie Morreale, Vice President and Minister of Employment, Training, Health, Social Action, Equal Opportunities and Women’s Rights; Willy Borsus, Vice-President and Minister of Economy, Foreign Trade, Research and Innovation, and Elio Di […]
February 04, 2022
Mr. Alexander De Croo, Prime Minister of Belgium, today formally opened a cutting-edge viral vector manufacturing facility in Jumet (Charleroi). The facility is run by Exothera, part of Univercells, a Belgian biotech company dedicated to ensuring that everyone, everywhere has access to biologics. Supported by the European Investment Bank, and completed in only 18 months, […]
January 26, 2022
Univercells S.A. (“Univercells”) management and Board of Directors, reached an agreement today with Timothy E. Morris to present him for official appointment as an independent director to its Board of Directors at the next annual general assembly on 8 February 2022. Mr. Morris brings over 38 years of professional finance and accounting experience and 25 […]
January 10, 2022
Hugues Bultot, CEO of Univercells Group, will present on Thursday, January 13 at 13.30 CET (7.30 a.m. ET). The presentation will be a live audio webcast and can be accessed via the following link.
January 05, 2022
Univercells S.A. (Univercells) today announced its acquisition of SynHelix, a biotechnology company that aims to debottleneck biotherapeutics development through an unprecedented robust, scalable and automated DNA synthesis technology resulting in one-step generation of long DNA fragments, at large quantities, high purity in a cGMP-compliant setup. SynHelix’s offering will complement the RNA platform being developed by […]
January 04, 2022
Univercells S.A. (“Univercells”) and Unizima S.A. (“the Company”), announce today the appointment of Hala Audi as Chief Executive Officer of Unizima, a Univercells Company dedicated to delivering facilities, services and expertise to meet local demand for biologics in low-to-middle-income countries. Hala’s appointment will bring the Company to its next level, driven by its mission of […]